What is Carmat?
Founded in 2008, Carmat is dedicated to developing cutting-edge artificial heart technology designed to combat chronic and acute heart failure, a critical global health concern. The company leverages a multidisciplinary approach, integrating advanced medical expertise with sophisticated engineering to create life-saving cardiac devices. With a presence spanning Europe, North America, and Asia, Carmat has established itself as a significant entity in the medical technology landscape, aiming to provide viable treatment alternatives for individuals with severe cardiac conditions. The company's transition to a public entity in 2019 marked a new phase in its growth and mission.
How much funding has Carmat raised?
Carmat has raised a total of $25.9M across 2 funding rounds:
Other Financing Round
$18.6M
Other Financing Round
$7.4M
Other Financing Round (2022): $18.6M with participation from EIC Accelerator
Other Financing Round (2023): $7.4M led by Sante Technology Holdings
Key Investors in Carmat
Sante Technology Holdings
Sante Technology Holdings Inc. is a diversified company involved in building materials, with a history that includes a name change from PEI Worldwide Holdings, Inc. in 2020. Its operations span the United States and international markets.
What's next for Carmat?
The recent major strategic investment signals a pivotal moment for Carmat, likely enabling accelerated research and development, expanded clinical trials, and broader market penetration for its artificial heart technologies. This financing is expected to bolster the company's capacity to scale its operations and further solidify its position in the competitive medical device industry, particularly in addressing the unmet needs of patients with end-stage heart failure. Carmat's strategic backing suggests a strong investor confidence in its long-term vision and technological innovation.
See full Carmat company page
